XML 25 R14.htm IDEA: XBRL DOCUMENT
v3.21.2

Deferred Revenue | 9 Months Ended
--- | ---
Sep. 30, 2021
Revenue From Contract With Customer [Abstract] |
Deferred Revenue |
7. | Deferred Revenue
Deferred revenue by revenue classification as of September 30, 2021 and December 31, 2020 was as follows (in thousands):
|  | September 30, 2021 |  |  | December 31, 2020 |
Current deferred revenue |  |  |  |  |  |  |  |
Sequencing |  | $ | 18,912 |  |  | $ | 15,463 |
Development |  |  | 61,042 |  |  |  | 57,856 |
Total current deferred revenue |  |  | 79,954 |  |  |  | 73,319 |
Non-current deferred revenue |  |  |  |  |  |  |  |
Sequencing |  |  | 126 |  |  |  | 724 |
Development |  |  | 110,512 |  |  |  | 162,894 |
Total non-current deferred revenue |  |  | 110,638 |  |  |  | 163,618 |
Total current and non-current deferred revenue |  | $ | 190,592 |  |  | $ | 236,937 |
Deferred revenue from our Genentech Agreement represents $57.5 million and $106.7 million of the current and non-current development deferred revenue balances, respectively, as of September 30, 2021 and $55.1 million and $157.0 million of the current and non-current development deferred revenue balances, respectively, as of December 31, 2020. In general, we expect that the current amounts will be recognized as revenue within 12 months and the non-current amounts will be recognized as revenue over a period of approximately five to six years from September 30, 2021. This period of time represents an estimate of the research and development period to develop cellular therapies in oncology, which may be reduced or increased based on the various development activities. During the nine months ended September 30, 2021, we recognized $3.4 million in revenue as a result of changes in estimates of total samples to be provided under certain of our agreements and cancelled biopharmaceutical customer sequencing contracts for which we had received upfront consideration. Additionally, we recognized $1.4 million and $2.0 million of sequencing revenue during the three and nine months ended September 30, 2021, respectively, related to Medicare reimbursements resulting from our determination that the likelihood of additional testing for specific patients was remote and a change in our estimate of expected cumulative tests per patient for one of our covered indications. Changes in deferred revenue during the nine months ended September 30, 2021 were as follows (in thousands):
Deferred revenue balance at December 31, 2020 |  | $ | 236,937 |
Additions to deferred revenue during the period |  |  | 26,720 |
Revenue recognized during the period |  |  | (73,065 | )
Deferred revenue balance at September 30, 2021 |  | $ | 190,592 |
As of September 30, 2021, $36.7 million was recognized as revenue that was included in the deferred revenue balance at December 31, 2020.

X
- Definition Deferred revenue. + References No definition available. + Details
Name: | adpt_DeferredRevenueTextBlock
Namespace Prefix: | adpt_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_RevenueFromContractWithCustomerAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration